Does Florida Blue Cover Mounjaro?
The verdict
Conditional on most plans
Florida Blue (BCBS of Florida) covers Mounjaro for type 2 diabetes with prior authorization via its Prime Therapeutics formulary, under tightened 2025 GLP-1 PA rules. Florida Blue does not cover Mounjaro for weight loss. The weight-loss tirzepatide product is Zepbound, with separate coverage. Florida Medicaid is diabetes-only and among the most restrictive states for weight-loss GLP-1 coverage.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Florida Blue (Blue Cross Blue Shield of Florida) using your member ID.
Key facts
Florida Blue uses Prime Therapeutics as its PBM and implemented a 2025 GLP-1 PA rule tightening prior-authorization requirements — complete A1c and metformin trial documentation is essential for Mounjaro approval.
Florida Blue / Prime Therapeutics, GLP-1 PA Policy Update, 2025
Florida Medicaid is diabetes-only on GLP-1 coverage and among the most restrictive states for weight-loss GLP-1 approval — Wegovy and Zepbound are not covered for obesity under FL Medicaid.
Florida Agency for Health Care Administration (AHCA) PDL, 2025
The 2026 Medicare Part D out-of-pocket cap is $2,100. Most Mounjaro users for diabetes who stay on therapy continuously reach this cap within 2–3 months and pay $0 for the rest of the year.
CMS Medicare Part D Redesign, 2026
Medicare vs. commercial coverage
Whether Florida Blue (Blue Cross Blue Shield of Florida) covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Florida Blue Medicare Advantage and Part D plans cover Mounjaro for type 2 diabetes only — not weight loss — with prior authorization via Prime Therapeutics. The 2026 Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach it within 2–3 months and pay $0 for the remainder of the year. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month), which covers weight-loss-approved products only. The Lilly savings card is not usable by Medicare or Medicaid beneficiaries.
Commercial / Employer
Group & marketplace plans
Florida Blue commercial and employer-sponsored plans: Mounjaro is covered for type 2 diabetes with prior authorization under the 2025 GLP-1 PA rule (Prime Therapeutics formulary). Florida Blue tightened its GLP-1 prior-auth requirements in 2025, requiring documented A1c and metformin trial — ensure the prescriber's submission is complete before submitting. Not covered for off-label weight loss. ACA/Individual: diabetes only, PA; weight-loss GLP-1s commonly excluded. Florida Medicaid: diabetes-only; among the most restrictive states for weight-loss GLP-1 coverage. Lilly savings card: $25/month with commercial coverage; $499/month without (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured without coverage (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
List price with no coverage — before any manufacturer savings card.
With coverage
Florida Blue plan-specific brand cost-share; tier not publicly confirmed at the drug level — verify on the Florida Blue drug lookup. Commercially insured with Mounjaro coverage may pay as little as $25/month via the Lilly savings card. Florida Medicaid: nominal copay for covered T2D use. Medicare Part D: 25% coinsurance to the $2,100 OOP cap 2026; MFN $245/month mid-2026.
Typical monthly copay once prior authorization is approved.
Bridge program
The 2026 Medicare GLP-1 Bridge ($50/month) covers weight-loss-approved products only; Mounjaro is not included.
Reduced copay through the assistance program, where eligible.
All figures are estimates; confirm cost-share on the Florida Blue drug lookup tool or Prime Therapeutics formulary. The Lilly savings card expires 12/31/2026 and is not available to Medicare, Medicaid, or government-program beneficiaries.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Verify Mounjaro coverage and tier on the Florida Blue drug lookup
Visit floridablue.com and use the drug formulary search to look up Mounjaro (tirzepatide) for your specific plan. Confirm whether PA is required (it is under the 2025 GLP-1 rule), what tier Mounjaro is on, and the current cost-share. Florida Blue's formulary is managed by Prime Therapeutics — tier placement should be verified for your plan year.
- 2
Have your prescriber submit a complete prior authorization under the 2025 GLP-1 PA rule
Florida Blue tightened GLP-1 PA criteria in 2025. Your prescriber must document your T2D diagnosis (ICD-10 E11.x), A1c of 6.5% or greater within ~90 days, and prior metformin trial (plus one additional agent). Incomplete documentation is the most common reason for delay or denial under the tightened rule. Allow up to 72 hours for a decision.
- 3
If you want tirzepatide for weight loss, ask about Zepbound — not Mounjaro
If your goal is weight loss rather than diabetes management, Mounjaro is the wrong product. The weight-loss tirzepatide is Zepbound, FDA-approved for chronic weight management and OSA. Florida is among the most restrictive states for weight-loss GLP-1 coverage — ask your prescriber and Florida Blue specifically about Zepbound coverage on your plan.
Options if Florida Blue (Blue Cross Blue Shield of Florida) won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. May be on a preferred tier ahead of Mounjaro as step therapy on Florida Blue / Prime Therapeutics formularies.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative that may be on a preferred tier; often serves as a step-therapy agent before Mounjaro approval.
Jardiance (empagliflozin)
SGLT2 inhibitor for T2D with cardiovascular benefits. May be required step therapy before GLP-1 approval on Florida Blue plans.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and OSA. Separate coverage track; Florida is among the most restrictive states for weight-loss GLP-1 coverage. Not a substitute for Mounjaro.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
No. Florida Blue does not cover Mounjaro for weight loss. Mounjaro is FDA-approved for type 2 diabetes only; the Prime Therapeutics PA is gated on a T2D diagnosis — off-label weight-loss requests are denied. For weight loss, the same active ingredient (tirzepatide) is Zepbound — a separate FDA approval. Florida is among the most restrictive states for weight-loss GLP-1 coverage, so Zepbound coverage is also limited.
Florida Blue tightened its GLP-1 prior-authorization requirements in 2025, making complete documentation — confirmed T2D diagnosis, A1c of 6.5% or greater within ~90 days, and documented metformin trial — more strictly enforced. Prescribers submitting incomplete PA requests for Mounjaro are more likely to receive denials or delays under the updated rule. Verify the current criteria on the Florida Blue formulary or Prime Therapeutics PA policy before submitting.
Florida Medicaid covers Mounjaro for type 2 diabetes with prior authorization. Florida Medicaid is diabetes-only on GLP-1 coverage and is among the most restrictive states for weight-loss GLP-1 coverage — so Zepbound and Wegovy are not covered for obesity under FL Medicaid. If you are on a Florida Medicaid plan, the Lilly savings card is not available to you; verify cost-share on your plan.
No. The 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027) covers weight-loss-approved products only — Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss. Florida Blue Medicare Advantage and Part D plans cover Mounjaro under standard Part D rules for T2D, with PA and the $2,100 annual OOP cap in 2026.
Related Articles
Does Blue Cross Blue Shield of Michigan Cover Mounjaro? | Curex
BCBS of Michigan covers Mounjaro for type 2 diabetes with PA, not weight loss. Zepbound weight-loss exclusion upheld by MI DIFS in 2025.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield of Arizona Cover Mounjaro? | Curex
BCBS of Arizona covers Mounjaro for type 2 diabetes with prior auth — not weight loss. AZ Medicaid covers Wegovy for weight loss, but not Mounjaro.
Read moreDoes BCBS of North Carolina Cover Mounjaro? 2026 | Curex
BCBS NC covers Mounjaro for type 2 diabetes with prior auth — not weight loss. The NC Medicaid weight-loss GLP-1 churn never affected Mounjaro.
Read moreDoes Florida Blue Cover Ozempic? 2026 Coverage Guide | Curex
Florida Blue covers Ozempic for T2D on its GLP-1 diabetes list — explicit commercial weight-loss exclusion. PA steps, copay estimates, 2026 cost facts.
Read moreDoes Florida Blue Cover Dupixent? 2026 Coverage Guide
Florida Blue covers Dupixent on the specialty tier via Prime Therapeutics with PA and step therapy. Coinsurance 25-33%; $2,100 Part D cap applies.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
You just saw how tangled Mounjaro coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Mounjaro. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Florida Blue (Blue Cross Blue Shield of Florida) before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.